基本资料 投资组合 财务数据 基金公告
汇添富纳斯达克生物科技ETF(QDII)(513290) |
净值：
1.1619
|
日增长率：
0.11%
|
累计净值：1.1619 | 2025-07-17 |
|
|
||||
| 股票代码 | 股票简称 | 持股数量(股) | 持股市值(元) | 占基金净值比(%) |
| AMGN | 安进 | 52,213.00 | 116,767,493.35 | 8.68 |
| AMGN | 安进 | 52,213.00 | 116,767,493.35 | 8.68 |
| VRTX | 福泰制药 | 33,524.00 | 116,668,043.19 | 8.67 |
| VRTX | 福泰制药 | 33,524.00 | 116,668,043.19 | 8.67 |
| GILD | 吉利德科学 | 140,711.00 | 113,176,293.01 | 8.41 |
| GILD | 吉利德科学 | 140,711.00 | 113,176,293.01 | 8.41 |
| REGN | 再生元制药 | 21,564.00 | 98,172,908.71 | 7.30 |
| REGN | 再生元制药 | 21,564.00 | 98,172,908.71 | 7.30 |
| AZN | 阿斯利康(US ADR) | 116,800.00 | 61,623,411.36 | 4.58 |
| AZN | 阿斯利康(US ADR) | 116,800.00 | 61,623,411.36 | 4.58 |
| ALNY | Alnylam Pharmaceuticals Inc | 25,967.00 | 50,330,734.16 | 3.74 |
| ALNY | Alnylam Pharmaceuticals Inc | 25,967.00 | 50,330,734.16 | 3.74 |
| BIIB | 生化基因 | 29,360.00 | 28,839,297.11 | 2.14 |
| BIIB | 生化基因 | 29,360.00 | 28,839,297.11 | 2.14 |
| ARGX | argenx SE ADR | 6,421.00 | 27,279,781.26 | 2.03 |
| ARGX | argenx SE ADR | 6,421.00 | 27,279,781.26 | 2.03 |
| SNY | 赛诺菲 | 57,637.00 | 22,945,461.00 | 1.71 |
| SNY | 赛诺菲 | 57,637.00 | 22,945,461.00 | 1.71 |
| SMMT | Summit Therapeutics Inc | 147,966.00 | 20,488,478.85 | 1.52 |
| SMMT | Summit Therapeutics Inc | 147,966.00 | 20,488,478.85 | 1.52 |
| 报告期 | 股票占净比(%) | 债券占净比(%) | 现金占净比(%) | 净资产(元) |
| 2025-03-31 | 86.03 | - | 0.63 | 1,345,089,030.94 |
| 2024-12-31 | 87.93 | - | 0.91 | 1,527,169,600.76 |
| 2024-09-30 | 87.03 | - | 0.96 | 1,360,481,855.81 |
| 2024-06-30 | 89.18 | - | 0.72 | 806,052,940.10 |
| 2024-03-31 | 88.47 | - | 0.90 | 1,323,750,633.74 |
微信公众号
证券之星APP
